Cairo – Mubasher: Pharos Research has set the fair value (FV) of the Egyptian International Pharmaceutical Industries Company (EIPICO) at EGP 95.3, with an overweight recommendation, according to a report released on Thursday.
EIPICO can enhance its operations through the introduction of new products and the revision of medicine prices, along with the reduction of cost pressures, the report said.
The consolidated income statements of EIPICO for the first six months of the fiscal year 2019 showed a marginal increase in profits when compared to the corresponding half a year earlier.
